Serenity by Quantgene Awarded “Functional Genomics Innovation of the Year” at BioTech Breakthrough Awards 2022

Annual Awards Program Honors Serenity, Which Provides World-Leading Accuracy in Precision Genomics and AI-Enabled Personalized Preventive Care

SANTA MONICA, Calif., Nov. 3, 2022Quantgene, a Santa Monica-based biotechnology, cloud and AI company, announced today its flagship product, Serenity, has been selected as the winner of the “Functional Genomics Innovation of the Year” award at the Biotech Breakthrough Awards 2022

The annual awards program is run by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe. The program conducts the industry’s most comprehensive analysis and evaluation of the top technology companies, solutions and products in the life sciences and biotechnology industry on an annual basis. This year’s program for 2022 attracted more than 1,350 nominations from rapidly growing startups to major industry players from all over the world, with notable winners from other categories, including Abbott, Honeywell, Pfizer, Brightseed, Quanterix and Vizgen.

“In our efforts to advance preventative care through precision genomics, we are honored to have BioTech Breakthrough recognize Quantgene’s Serenity,” said Jo Bhakdi, founder and CEO of Quantgene. “As Quantgene is the first to launch liquid biopsy cancer detection with whole exome sequencing and advanced medical intelligence, this industry recognition strengthens our mission to unlock the ability to detect cancer mutations early. Serenity closes the preventative care gap by detecting and reducing the biggest medical risks before they become health threats. We will continue to work diligently as Quantgene brings this reality to the masses.” 

Quantgene’s Serenity combines advanced next-generation sequencing with proprietary cloud and AI technology to uncover deeper, more meaningful insights into disease and disease risk status at earlier stages. Serenity’s unique blend of medicine and technology allows for early intervention to ensure better treatment response and long-term outcomes for potentially fatal conditions such as cancer. 

Quantgene has launched clinical trials with City of Hope, Prisma Health and University of Arizona oncology departments to take leaps in precision medicine and early detection for cancer. Serenity has various products that are being introduced in Q4 2022 and Q1 2023. 


About Quantgene

Quantgene was founded in 2015 at UC Berkeley with the mission to detect cancer and other diseases early and protect human life. Now based in Santa Monica, California, with offices in Portland, Oregon, and Berlin, Quantgene has galvanized a team of scientists and technologists to push the boundaries of precision and preventive medicine. With the backbone of a world-leading laboratory infrastructure and AI-powered cloud systems, Quantgene has utilized its talent and technology to transform healthcare through three business units: Apollo, Pandemic Protect, and Serenity.

Apollo deploys the world’s most advanced medical intelligence system to close the care gap in precision preventive medicine and chronic care management for providers and large systems. Pandemic Protect has kept Hollywood’s entertainment industry in business and has partnered with government agencies coast-to-coast, keeping US citizens safe. Using superior data and intelligence to detect genetic and real-time medical risks, Serenity aims to extend the healthy human lifespan by a decade within a decade. 

Learn more at quantgene.com.

About Serenity

Serenity has the mission to extend the healthy human lifespan by a decade within a decade through preventive, precision medicine. With the world’s most advanced preventive care system, Serenity uses superior data and intelligence to detect hereditary and real-time medical risks before they become health threats.

Powered by a vertically integrated technology stack, world-class Medical Intelligence Team and a unique genomics assessment, Serenity turns data and intelligence into medically actionable preventive guidance for members.

Serenity combines your diagnostic data with AI and human medical intelligence to create a personal health protection system, delivered to the palm of your hand through a simple portal. Through a combination of at-home concierge visits and digital consultations, Serenity provides a new level of medical protection at times and locations suited to its members.

Learn more at chooseserenity.com.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information, visit biotechbreakthroughawards.com.

Fred Hulls
September 21

People Science™ and ScaleHealth Partner to Validate Innovative Healthcare Solutions

The partnership will leverage comprehensive virtual clinical research technology inpeople-forward research to bring novel health solutions to the forefront.